Search

Your search keyword '"Cree, B."' showing total 145 results

Search Constraints

Start Over You searched for: Author "Cree, B." Remove constraint Author: "Cree, B."
145 results on '"Cree, B."'

Search Results

9. P 4 The impact of low affinity immunoglobulin gamma Fc region receptor III-A gene polymorphisms in neuromyelitis optica spectrum disorder and implications for treatment outcomes: results from the N-MOmentum study

10. P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials

17. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

20. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures

21. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

23. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring

24. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

25. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

26. Health-related quality of life in multiple sclerosis: Effects of natalizumab

27. Magnetic resonance spectroscopy effects of natalizumab:single center results from the SENTINEL study

28. The incidence and significance of anti-natalizumab antibodies. Results from the AFFIRM and SENTINEL

29. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

30. Unusual variants of Alexander's disease (vol 57, pg 327, 2005)

32. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

33. Genetic risk variants in African Americans with multiple sclerosis

34. Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis

36. RESTORE Study: Effects of a 24-Week Natalizumab Treatment Interruption on Immune Parameters and Multiple Sclerosis Magnetic Resonance Imaging Disease Activity (P06.168)

38. Effects of a 24-Week Natalizumab Treatment Interruption on Quality of Life, Fatigue, and Cognition: Results from the RESTORE Study (P06.171)

39. Association of Targeted Blood Biomarkers with Interferon Beta-1a Treatment Administration, Magnetic Resonance Imaging Activity, and Treatment Response (P02.089)

43. Multiple sclerosis susceptibility alleles in African Americans

Catalog

Books, media, physical & digital resources